X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PFIZER - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PFIZER BIOCON LTD/
PFIZER
 
P/E (TTM) x 75.1 28.8 261.0% View Chart
P/BV x 7.1 4.6 154.5% View Chart
Dividend Yield % 0.2 0.7 24.8%  

Financials

 BIOCON LTD   PFIZER
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
PFIZER
Mar-16
BIOCON LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,1622,724 42.7%   
Low Rs4831,611 30.0%   
Sales per share (Unadj.) Rs194.6440.9 44.1%  
Earnings per share (Unadj.) Rs34.448.7 70.7%  
Cash flow per share (Unadj.) Rs48.375.8 63.7%  
Dividends per share (Unadj.) Rs1.0015.00 6.7%  
Dividend yield (eoy) %0.10.7 17.6%  
Book value per share (Unadj.) Rs241.9462.9 52.2%  
Shares outstanding (eoy) m200.0045.75 437.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.9 86.0%   
Avg P/E ratio x23.944.5 53.7%  
P/CF ratio (eoy) x17.028.6 59.6%  
Price / Book Value ratio x3.44.7 72.6%  
Dividend payout %2.930.8 9.4%   
Avg Mkt Cap Rs m164,44099,163 165.8%   
No. of employees `0009.22.9 319.6%   
Total wages/salary Rs m7,4702,758 270.9%   
Avg. sales/employee Rs Th4,213.96,981.7 60.4%   
Avg. wages/employee Rs Th809.0954.5 84.8%   
Avg. net profit/employee Rs Th745.2771.1 96.6%   
INCOME DATA
Net Sales Rs m38,91120,170 192.9%  
Other income Rs m1,571857 183.2%   
Total revenues Rs m40,48221,028 192.5%   
Gross profit Rs m9,7954,310 227.3%  
Depreciation Rs m2,7721,239 223.8%   
Interest Rs m2605 5,000.0%   
Profit before tax Rs m8,3343,923 212.4%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m1,6161,794 90.1%   
Profit after tax Rs m6,8812,228 308.9%  
Gross profit margin %25.221.4 117.8%  
Effective tax rate %19.445.7 42.4%   
Net profit margin %17.711.0 160.1%  
BALANCE SHEET DATA
Current assets Rs m40,47716,299 248.3%   
Current liabilities Rs m16,7837,594 221.0%   
Net working cap to sales %60.943.2 141.1%  
Current ratio x2.42.1 112.4%  
Inventory Days Days6065 91.3%  
Debtors Days Days8326 321.7%  
Net fixed assets Rs m45,0738,622 522.8%   
Share capital Rs m1,000458 218.6%   
"Free" reserves Rs m47,37720,722 228.6%   
Net worth Rs m48,37721,180 228.4%   
Long term debt Rs m21,08225 84,328.0%   
Total assets Rs m93,94229,137 322.4%  
Interest coverage x33.1755.5 4.4%   
Debt to equity ratio x0.40 36,919.6%  
Sales to assets ratio x0.40.7 59.8%   
Return on assets %7.67.7 99.2%  
Return on equity %14.210.5 135.2%  
Return on capital %12.619.0 66.4%  
Exports to sales %00.1 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs mNA3,526 0.0%   
Fx inflow Rs m12,98852 25,146.2%   
Fx outflow Rs m7,899140 5,642.9%   
Net fx Rs m5,089-88 -5,761.3%   
CASH FLOW
From Operations Rs m6,4003,436 186.2%  
From Investments Rs m-4,985-6,991 71.3%  
From Financial Activity Rs m-1,775-619 286.8%  
Net Cashflow Rs m-473-4,174 11.3%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 63.9 32.2%  
Indian inst/Mut Fund % 8.4 7.5 112.0%  
FIIs % 10.7 4.9 218.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.7 84.0%  
Shareholders   109,995 85,207 129.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  FULFORD INDIA  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 19, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS